L’exposition prénatale à différents agents toxiques est généralement étudiée en considérant le placenta comme une barrière entre la mère et le fœtus ; nous le considérons en tant qu’organe cible des agents toxiques. Pour ce faire, nous avons sélectionné un modèle cellulaire de trophoblastes adapté aux études toxicologiques. En clinique, des pathologies de la grossesse sont associées à des modifications de la sécrétion de l’hormone placentaire lactogène hPL et de l’hormone gonadotrope chorionique hCG. Nos travaux in vitro ont permis de faire le lien entre une exposition à des micropolluants (le mono(2-ethylhexyl) phtalate, un perturbateur endocrinien, et le benzo(a)pyrene, un carcinogène) et ces observations cliniques. Les biomarqueurs de sécrétion hormonale (hPL et hCG hyperglycosylée) et de dégénérescence (activation du purinorécepteur P2X7) que nous avons identifiés permettent de détecter l’exposition et le risque suite à une exposition à des polluants. / Prenatal exposure to pollutants is commonly evaluated using placenta as a barrier between mother and fetus. Here, we consider placenta as a target organ for toxic agents. To achieve this, we selected a trophoblastic cell model, which is adapted to toxicological studies. In clinical studies, pregnancy pathologies are associated to changes in human placental lactogen (hPL) and human chorionic gonadotropin (hCG) secretions. Our in vitro work links exposure to micropollutants (mono(2-ethylhexyl)phthalate, an endocrine disruptor, and benzo(a)pyrene, a carcinogen) and clinical observations. We identified biomarkers of hormonal secretion (hPL and hyperglycosylated hCG) and degeneration (P2X7 receptor activation), which enable the evaluation of exposure and risk attached to exposure to pollutants.

2011年5月臺灣爆發不肖業者將具有毒性之塑化劑添加入合法食品添加物─起雲劑當中，販賣給多家食品業者，用以生產各種食品及飲料，戕害國民健康。惟案件中消費者僅獲賠求償額的兩千分之一，差距甚大，明顯不如預期，更是引發社會諸多撻伐。本論文藉由上述塑化劑案件，探討食品安全消費訴訟消費者求償困境並檢討現行法的缺失與不足，以符合消費者權益保障之宗旨。 文章中首先針對食品安全消費訴訟特性以及我國食品管制上主管機關的權責劃分進行概念性介紹，並就訴訟中消費者可主張的民法、消費者保護法、食品安全衛生管理法上請求權基礎進行要件及爭點說明。其次，就損害賠償之概念及損害進行界定與討論。另由於此類型訴訟，消費者食用問題產品後，多半不會產生立即性身體傷害或臨床病徵，導致訴訟上消費者就其所受之損害難以舉證而敗訴，故本文藉由參酌美國毒物侵權行為訴訟上之損害認定，將損害概念擴張至損害或「損害之虞」，以解決訴訟上消費者損害認定不易的難題。 此外，於因果關係舉證方面，則藉由德國環境責任法、德國基因科技法上之原因推定理論、美國法上市場佔有率責任之因果關係以及日本法上疫學因果關係理論，作為此類型訴訟我國因果關係認定之參考，並就損害賠償範圍、我國懲罰性賠償金制度的引進、目的、重要爭點等析述討論之。最後，本論文藉由實務上判決，觀察現行食品安全衛生管理法第56條法院適用情形，從中檢討現行條文不盡完備之處，並嘗試提出相關修法建議，希冀可作為將來立法者修法之參考。 / In May, 2011 the Taiwan Food and Drug Administration reported that plasticizers, such as: di(2-ethylhexyl)phthalate (DEHP) and di(iso-nonyl)phthalate (DINP), were illegally added to clouding agents used in foods and several beverages.The endocrine disruptors have been linked to developmental problems with children and pregnant women, etc.This paper would mainly discuss the issues of the reflection of civil liabilities arising from food scandals, particularly focus on the plasticizer food scandal in Taiwan. First, the author gives an overview of consumer litigation of food safety, food administration in Taiwan, and the basic of claim such as the Civil law, the Act Governing Food Safety and Sanitation as well as the Consumer Protection Law.Secondly, interprets the concept of civil compensationand expand the traditional concept of personal injury to risk of injury (the plaintiff has not manifested any symptoms of disease but may suffer from illness in the future) by referring to toxic tort.Thirdly, illustrates the special rules on causation in the aspect of the environmental liability law, the biotech law and the market share liability to solve the problems of the causation.Fourthly,probes the compensation scope and punitive damages. Finally,by observing court decisions on article 56 of the Act Governing Food Safety and Sanitation, the author analyzes the deletion of existing legal norms and suggests a proposal for law amendments.

El di(2-etilhexil) ftalat (DEHP) és un plastificant que s’afegeix als productes de clorur de polivinil (PVC) per a dotar-los de més flexibilitat. El material mèdic fet de PVC, i en particular els dispositius i bosses que s’utilitzen en les transfusions de sang, conté el DEHP com additiu. Així, el receptor d’una transfusió està altament exposat a aquest compost. L’objectiu de la tesi va ser estudiar els metabòlits del DEHP en orina com a possibles marcadors de la pràctica d’una transfusió de sang en l’esport. Es va desenvolupar i validar un mètode d’anàlisi per cromatografia líquida acoblada a espectrometria de masses en tàndem per a la quantificació dels principals metabòlits del DEHP en orina humana: mono-(2-etilhexil) ftalat (MEHP), mono-(2-etil-5-hidroxihexil) ftalat (MEHHP), mono-(2-etil-5-oxohexil) ftalat (MEOHP), mono-(2-carboximetilhexil) ftalat (2cx-MMHP) i mono-(2-etil-5-carboxipentil) ftalat (5cx-MEPP). El mètode es va aplicar a mostres procedents de voluntaris sans (grup control), de pacients hospitalitzats que havien rebut una transfusió de sang i de pacients hospitalitzats sotmesos a tractaments mèdics amb materials de PVC i no a transfusions. Es van obtenir diferències significatives en les concentracions dels tres metabòlits estudiats (MEHP, MEHHP, MEOHP) entre les mostres dels pacients transfosos respecte els altres dos grups de població. El mètode també es va aplicar a mostres d’orina de vint-i-cinc voluntaris sans que s’havien sotmès a un procediment d’autotransfusió. Els resultats van indicar concentracions elevades dels cinc metabòlits del DEHP en orina fins a les 48 hores després d’haver rebut la sang. Finalment, es van determinar les concentracions dels cinc metabòlits de DEHP en una població d’esportistes i es van calcular límits de referència que permetessin sospitar d’una transfusió. Així doncs, els resultats indiquen que la mesura dels metabòlits de DEHP en orina pot ser usada com una eina pel cribatge de l’ús de transfusions en l’esport. / The plasticizer di(2-ethylhexyl)phthalate (DEHP) is used in polyvinyl chloride products (PVC) to increase its flexibility. Medical devices made of PVC, especially blood bags used in blood transfusions, contain DEHP as additive. Therefore, subjects submitted to blood transfusion are widely exposed to this compound. The aim of the project was to evaluate DEHP metabolites in urine as possible markers of the use of a blood transfusion in sports. An analytical method was developed and validated to quantify the main DEHP metabolites mono-(2-ethylhexyl)phthalate (MEHP), mono-(2-ethyl-5-hydroxyhexyl)phthalate (MEHHP), mono-(2-ethyl-5-oxohexyl)phthalate (MEOHP), mono-(2-carboxymethylhexyl)phthalate (2cx-MMHP) and mono-(2-ethyl-5-carboxypentyl)phthalate (5cx-MEPP), in human urine by liquid chromatography tandem mass spectrometry. The methodology was applied to samples belonging to healthy volunteers (control group), hospitalized patients subjected to blood transfusions and hospitalized patients subjected to medical treatments involving plastic material different to blood transfusions. Significant differences were obtained in the concentrations of the three metabolites studied (MEHP, MEHHP, MEOHP) between transfused patients samples’ and the other two population groups. The method was also applied to urine samples from twenty-five healthy volunteers who were subjected to an autologous blood transfusion. The results indicated high concentrations of the five DEHP metabolites in urine up to 48 hours after the blood transfusion. Finally, the concentration of the five DEHP metabolites were evaluated in a sportsmen population and reference limits to allow suspicion of blood transfusion were calculated. Thus, the results indicate that the DEHP metabolites could be used as markers of blood transfusions in sports.